Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
06:02pAllergan PLC. $AGN Position Lifted by Perpetual Ltd  
04:06pSentry Investment Management LLC Has $6.54 Million Holdings in Allergan PLC. .. 
11:36aAllergan PLC. $AGN Given a $255.00 Price Target at UBS AG  
07:38aAllergan, Restasis and the Mohawks vs. the Feds: Epic fail? $AGN  
10/20Allergan: A Splitting Headache?
2
10/20Allergan: A Splitting Headache?  
10/20  
10/20  
10/20What Brent Saunders Thinks About a Possible Allergan Breakup
1
10/20Allergan's Frown Lines Deepen: Time To Reevaluate Management  
10/20Allergan PLC. $AGN Holdings Trimmed by Wasatch Advisors Inc.  
10/20Buzz: Will Brent Saunders split up Allergan if he loses the Restasis patent f..
1
10/20Allergan PLC.'s outperform rating reiterated at Cowen and Company. $280.00 PT.. 
10/20Allergan's stock-price struggles sure to trigger breakup questions: analyst: .. 
10/20Allergan stock price target cut to $275 from $300 at J.P. Morgan #news 
10/20Allergan $AGN: Cutting PT To $280 From $400 - Cowen
3
10/2038 Biggest Movers From Yesterday  
10/20The Market In 5 Minutes: Chaos In Catalonia, Black…  
10/20Allergan PLC. $AGN Cut to Sell at Zacks Investment Research  
10/20
1
10/20Imprimis Pharma to take on Allergan's Restasis with cheaper product
1
10/20Imprimis Pharma to take on Allergan's Restasis with cheaper product
11
10/20Imprimis Pharma to take on Allergan's Restasis with cheaper product  
10/20Imprimis Pharma to take on Allergan's Restasis with cheaper product
4
10/20Imprimis Pharma to take on Allergan's Restasis with cheaper product  
10/20Imprimis Pharma to take on Allergan's Restasis with cheaper product
1
10/20.Allergan, Restasis and the Mohawks vs. the Feds: Epic fail? $AGN  
10/19  
10/19A judge calls foul on Allergan's attempt to hide its drug patents behind an I..
2
10/19  
10/19Trending: $AGN stock trouble to prompt breakup questions, analyst says
4
10/19Allergan, Restasis and the Mohawks vs. the Feds: Epic fail? $AGN  
10/19Allergan, Restasis and the Mohawks vs. the Feds: Epic fail? $AGN  
10/19Allergan PLC. $AGN Trading Down 1% After Analyst Downgrade  
10/19Imprimis Pharma to take on Allergan's Restasis with cheaper product  
10/19Imprimis Launches 99-Cent Generic Drug To Compete With Allergan's Restasis  
10/19Here are the top five stocks analysts are bearish on today. Here's why:
1
10/19Allergan PLC. $AGN Stake Maintained by HighPoint Advisor Group LLC  
10/19Imprimis Pharma to take on Allergan's Restasis with cheaper product
1
10/19$AGN likely to face breakup speculation, analyst says
1
10/19Allergan: All In or Fall Out?  
10/19National Asset Management Inc. Boosts Stake in Allergan PLC. $AGN  
10/19On The Fly: Top five analyst downgrades $NKE $S $HAIN $AGN $MAA
2
10/19Imprimis Pharma to offer compounded alternatives to Allergan's Restasis; shar.. 
10/19The Market In 5 Minutes: Chaos In Catalonia, Black Monday's 30th Anniversary .. 
10/19Thursday's Top Analyst Upgrades & Downgrades $ADBE $AGN $AXP $BHGE $NKE $..
1
10/19Thursday's Top Analyst Upgrades & Downgrades $ADBE $AGN $AXP $BHGE $NKE .. 
10/19Allergan downgraded to neutral by Mizuho after Restasis patent loss #news 
10/19Traders Buy Shares of Allergan PLC. $AGN on Weakness
1
10/19Allergan faces a cheaper, compounded version of Restasis eye drops..  
10/19Imprimis Launches 99-Cent Generic Drug To Compete With Allergan's Restasis
1
10/19Allergan PLC. $AGN PT Lowered to $240.00 at Citigroup Inc.  
10/19Allergan PLC.'s buy rating reiterated at Royal Bank Of Canada. $250.00 PT.  
10/19Allergan PLC.'s PT cut by Citigroup Inc. to $240.00. buy rating.  
10/19Allergan PLC. downgraded by Mizuho to neutral.  
10/19Allergan $AGN: Cutting PT On Increasing Generic Competition - RBC  
10/19Analysts Offer Insights on Healthcare Companies: Allergan (NYSE: AGN) and Abb.. 
10/19Mizuho Securities Downgrades Allergen $AGN to Neutral  
10/19Allergan PLC. $AGN PT Set at $243.00 by Credit Suisse Group  
10/19Allergan Issues Investor FAQ on Federal District Court RESTASIS® Patent Decis.. 
10/19Bears are profiting from $AGN losses
1
10/19Bears are profiting from $AGN losses
1
10/19  
10/19The Biggest Loser: Allergan?s Patent Troubles  
10/18$DISH $FL $AGN and $WDC are four of the stocks that analysts say still have s..
2
10/18Allergan is our most-clicked stock of the day. Here's why:
6
10/18The stock rallied more than 1,400% from its 2009 low to its 2015 high $AGN
3
10/18? TODAY'S ACTIVE FLOW: $BAC $AAPL $IBM $NFLX $FB $MU $TSLA $BABA $NVDA $JD $C..
1
10/18#Allergan ruling casts doubt on tribal #patent strategy  
10/18Allergan's stock has tumbled 9.1% this week after court rules against co.'s p.. 
Next »
Qtime:508
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 624 M
Net income 2017 -3 984 M
Debt 2017 24 537 M
Yield 2017 1,55%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,50x
EV / Sales 2018 5,24x
Capitalization 62 943 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 241 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC-10.89%62 943
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223